Clinical trial
Open-label Extension Study to Evaluate Longer-Duration Response to the NTX100 Neuromodulation System for Patients With Medication-Refractory Primary Restless Legs Syndrome (RLS)
NCT05196828 is registered in ClinicalTrials.gov with Noctrix Health, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-label Extension Study to Evaluate Longer-Duration Response to the NTX100 Neuromodulation System for Patients With Medication-Refractory Primary Restless Legs Syndrome (RLS)
- Lead sponsor
- Noctrix Health, Inc.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- December 20, 2021
- Completion date
- November 18, 2022
- Enrollment
- 103 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.